Pulmatrix Inc (NASDAQ:PULM) – Equities researchers at Zacks Investment Research issued their Q1 2018 earnings per share estimates for Pulmatrix in a research note issued on Wednesday. Zacks Investment Research analyst A. Dushyanth forecasts that the biotechnology company will post earnings per share of ($0.20) for the quarter. Zacks Investment Research also issued estimates for Pulmatrix’s Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.70) EPS, FY2019 earnings at ($0.70) EPS and FY2020 earnings at $1.50 EPS.

How to Become a New Pot Stock Millionaire

PULM has been the topic of a number of other research reports. HC Wainwright cut their price target on shares of Pulmatrix to $3.00 and set a “buy” rating on the stock in a report on Friday, March 16th. ValuEngine upgraded shares of Pulmatrix from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Pulmatrix (NASDAQ:PULM) opened at $1.11 on Friday. Pulmatrix has a twelve month low of $1.06 and a twelve month high of $3.84.

A hedge fund recently raised its stake in Pulmatrix stock. Vanguard Group Inc. grew its stake in Pulmatrix Inc (NASDAQ:PULM) by 8.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,758 shares of the biotechnology company’s stock after purchasing an additional 7,351 shares during the period. Vanguard Group Inc. owned about 0.52% of Pulmatrix worth $240,000 as of its most recent SEC filing. 20.11% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Comments on Pulmatrix Inc’s Q1 2018 Earnings (PULM)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/zacks-investment-research-comments-on-pulmatrix-incs-q1-2018-earnings-pulm/1959480.html.

About Pulmatrix

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.